Expression of the multi-drug resistance proteins and the pregnane X receptor in treated and untreated retinoblastoma

Current Eye Research

Volumn 34, Issue 5, 2009, Pages 386-394

  Wilson, Matthew W ^a,c   Fraga, Charles H ^b   Rodriguez Galindo, Carlos ^b   Hagedorn, Nikolas ^b   Leggas, Markos L ^b   Stewart, Clinton ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c FACS   (United States)

Author keywords

Chemotherapy; MRP 1 P glycoprotein; Multi drug resistance; Pregnane X receptor; Retinoblastoma

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; PREGNANE X RECEPTOR; VINCRISTINE; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; STEROID RECEPTOR; TUMOR PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATIONAL STUDY; ENUCLEATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; TISSUE MICROARRAY; TREATMENT FAILURE; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG THERAPY; GENE EXPRESSION; METABOLISM; MICROARRAY ANALYSIS; RADIOTHERAPY; RETINA TUMOR;

ATP-BINDING CASSETTE TRANSPORTERS; CHILD; COHORT STUDIES; DRUG THERAPY; EYE ENUCLEATION; GENE EXPRESSION; HUMANS; MICROARRAY ANALYSIS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RADIOTHERAPY; RECEPTORS, STEROID; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 67649649882     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680902859621     Document Type: Article

References (32)

1. Ellsworth RM. Practical management of retinoblastoma. Trans Am Ophthalmol Soc 1969;67:462-534.
2. Abramson DH, Frank CM. Second non-ocular tumors in survivors of bilateral retinoblastoma: A possible age effect on radiation-related risk. Ophthalmology 1998;105:573-579.
3. Wilson MW, Rodriguez-Galindo C, Haik BG, Moshfeghi DM, Merchant TE, Pratt CB. Multi-agent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 2001;108:2106-2115.
4. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003;21:2019-2025.
5. Shields CL, De Potter P, Himelstein B, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1330-1338.
6. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000;18:12-17.
7. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996;114:1321-1328.
8. Murphree AL, Villablanca JG, Deegan WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1348-1356.
9. Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Resultsofcombinedchemotherapyandradiotherapyforadvanced intraocular retinoblastoma. Arch Ophthalmol 1996;114:1339-1343.
10. Greenwald MJ, Strauss LC. Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy. Ophthalmology 1996;103:1989-1997.
11. Shields CL, Shields JA, Needle M, et al. Combined chemore-duction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997;104:2101-2111.
12. Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent external beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 2000;18:2881-2887.
13. Brichard B, Brucycker JJ, DePotter P, Neven B, Vermylen C, Cornu G. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol 2002;38:411-415.
14. Chan HS, Canton MD, Gallie BL. Chemosensitivity and multidrug resistance to anti-neoplastic drugs in retinoblastoma cell lines. Anticancer Res 1989;9:469-474.
15. Chan HS, Thorner PS, Haddad G, Gallie BL. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology 1991;98:1425-1431.
16. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma with requiring radiation. Clin Cancer Res 1996;2:1499-1508.
17. Chan HS, Lu Y, Grogan TM, et al. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 1997;57:2325-2330.
18. DeanM,RzhetskyA,AllikmetsR.The human ATP-bindingcassette (ABC) transporter superfamily. Genom Res 2001;11:1156-1166.
19. List AF, Kopecky KJ, William CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 2001;98:3212-3220.
20. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-1232.
21. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologists 2003;8:411-424.
22. Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, Hiramatsu Y. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol 2005;19:1170-1180.
23. Synold TW, Dussault I, Forman BM. The orphan nucleotide receptor SXR coordinately regulates drug metabolism and efflux. Nature Med 2001;7:584-590.
24. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, et al. Expression of the drug transporters, MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their with expression in intestine and liver. Biochem Pharmacol 2005;70:949-958.
25. Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor up-regulation of P-glycoprotein expression and transport at the blood brain barrier. Mol Pharmacol 2004;66:413-419
26. Kauffmann HM, Pfannschmidt S, Zöller H, et al. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 2002;171:137-146.
27. Wilson MW, Fraga CH, Fuller CE, et al. Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest Ophthalmol Vis Sci 2006;47:1269-1273.
28. Kyndi M, Sørensen FB, Knudsen H, et al. Tissue microarrays compared with wholesections and biochemical analyses.Asubgroup analysis of DBCG 82 b&c. Acta Oncol 2008;47:591-599.
29. Krishnakumar S, Mallikakarjuna K, Desai N, et al. Multidrug resistance proteins: P-glycoprotein expression in retinoblastoma. Br J Ophthalmol 2004;88:1521-1526.
30. Huang, R, Murry DJ, Kolwankar D, Hall SD, Foster DR. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol 2006;71:1695-1704.
31. Wilson TW, Chan HS, Moselhy GM, Heydt Jr DD, Frey CM, Gallie BL. Penetration of chemotherapy into the vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol 1996;114:1390-1395.
32. Koyano S, Kouichi K, Saito Y, et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): One variant causes dramatic loss of both DNA binding activity and the transactivation of theCYP3A4 promoter/enhancer region. Drug Metab Dispos 2004;32:149-154.